Article
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815…
Read More
Neumora to develop and commercialize M4-selective muscarinic receptor positive allosteric modulator program for schizophrenia and other neuropsychiatric disorders Neumora gains two novel series of M4 receptor modulator compounds in late preclinical development Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Neumora Therapeutics, Inc. (Neumora), a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the…
Read More
Research collaboration will utilize Repertoire’s DECODE™ platform to identify specific T cell receptors and antigens causing onset and progression of autoimmune disease vitiligo, with goal of developing targeted immunotherapy Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Repertoire Immune Medicines, Inc. today announced it has entered a sponsored research agreement with UMass Chan Medical School (UMass Chan)…
Read More
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years U.S. FDA has assigned a target action date of June 24, 2022 Excerpt from the…
Read More
Myrtelle’s Phase 1/2 clinical trial introduces first-of-its-kind proprietary recombinant adeno-associated virus (rAAV) vector designed to enable targeting of oligodendrocytes To date, 3 patients received gene therapy with the rAAV vector at a dose of 3.7 x 1013 vg delivered via intracerebroventricular administration Available follow-up data in treated patients demonstrate favorable safety and tolerability with encouraging initial…
Read More
Excerpt from the Press Release: Collaboration Enables Further Expansion of Mass Cytometry in the Middle East SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration agreement with the Abu Dhabi Stem Cells Center (ADSCC) for…
Read More
SPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg Results support further development of SPR206 in the setting of hospital-acquired pneumonia and ventilator-associated pneumonia Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced…
Read More
Excerpt from the Press Release: FREDERICK, Md. and BOSTON, Feb. 15, 2022 /PRNewswire/ — Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for its OsteoAdapt SP Spinal Fusion implant indicated for posterolateral spinal fusion to treat degenerative disc disease, spondylolisthesis,…
Read More
Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-235, a coronavirus 3CL protease inhibitor (also known as the main coronavirus…
Read More
– Continued positive efficacy and durability with stable visual acuity (VA) and optical coherence tomography (OCT) through eight-month follow-up – 41% of eyes remained rescue free up to nine months after a single dose of EYP-1901 – Positive safety data continued with no dose limiting toxicities, no ocular serious adverse events (SAEs) and no drug-related…
Read More